Martina Ott joined Immatics in September 2023 and leads the Department for TCR Delivery & Validation. Her department is responsible for preclinical efficacy and safety testing of TCRs used for ACT or soluble TCR bispecifics as well as for the development of cell engineering approaches for innovative ACT. Additionally, the refolding unit of peptide-MHC complexes is part of the department.
Martina was trained as a postdoctoral fellow at the DKFZ in Heidelberg, before she spent 6 years at the MD Anderson Cancer Center in Houston. Her research focused on pre-clinical development of immunotherapeutic approaches for solid cancers as well as on Immunomonitoring of early clinical trials. Afterwards she joined Miltenyi Biotec as a group leader responsible for the development of cell-based cancer therapies, Immunomonitoring & TCR analytics.
Martina obtained her Tumor Immunology-focused PhD from the University in Heidelberg and holds a Diploma in Biology from the University in Würzburg.